tiprankstipranks

Iveric bio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield downgraded Iveric bio (ISEE) to Neutral from Buy with a price target of $40, up from $35, after the company entered into a definitive agreement to be acquired by Astellas Pharma (ALPMY) for $40 per share, which represents an equity value of $5.9B.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ISEE:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue